ALTERITY THERAPEUTICS LTD (PRNAF)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Alterity Therapeutics Limited
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 11, 2026 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 2,500 |
| Nov 5, 2026 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 5,000 |
| Nov 3, 2026 | 0.2000 | 0.2422 | 0.2000 | 0.2422 | 7,500 |
| Oct 12, 2026 | 0.2500 | 0.2500 | 0.2500 | 0.2500 | 2,500 |
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases.
Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease.
The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
Parent ATHE: 2.03% · 23 13F holders
30d Avg
5.00K
60d Avg
4.38K
90d Avg
4.00K
Alterity Therapeutics Ltd (OTC: PRNAF) traded at $0.2000 on Nov 11, 2026, unchanged from the previous close of $0.2000. 52-week range: $0.0450 to $0.5501. The company is in the Healthcare sector (Biotechnology).